Recommendation of the President – Quviviq (daridorexant)
On 8 January 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 162/2024 on the appropriateness of granting approval for the reimbursement of the medicinal product Quviviq (daridorexant) for the indication: inorganic insomnia